Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit

Key Points

• Entrada expects a “data-rich” 2026, with first clinical data for ENTR-601-44 (exon 44) at 6 mg/kg due in Q2 (company expects double-digit dystrophin) and a second cohort up to 12 mg/kg before year-end, while ENTR-601-45 cohort data are expected mid-year.
• Entrada’s EEV/CPMP delivery platform (cyclic cell-penetrating peptide chemistry) is presented as a safety-differentiated approach with preclinical and healthy-volunteer safety data and could de-risk the wider DMD and Vertex-partnered DM1 programs if Q2 results are positive.
• U.S. dosing and enrollment hinge on Q2 readout: the FDA currently caps U.S. dosing at ~1.28 mg/kg, Entrada plans to review the 6 mg/kg data and seek higher U.S. dose allowances and may delay the planned adult U.S. study (targeted for H2) pending regulator discussions.

Entrada Therapeutics NASDAQ: TRDA used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to outline its pipeline focus on intracellular therapeutics and to preview multiple clinical data catalysts expected in 2026, particularly in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

Company focus and platform

CEO Dipal Doshi described Entrada as a Boston-based company with roughly 150–160 employees developing “intracellular therapeutics.” The company’s approach uses a proprietary delivery mechanism it calls endosomal escape vehicles (EEVs), designed to help deliver therapeutics inside cells. Doshi said the pipeline is currently led by programs in DMD and DM1.

Doshi also noted that Entrada recently announced entry into ocular diseases, with an initial focus on inherited retinal diseases. The first ocular indication the company disclosed is Usher syndrome type 1A.

2026 data expectations: DMD exon 44 and exon 45

Doshi characterized 2026 as a “data-rich year” and laid out several expected clinical readouts. In DMD, he highlighted planned clinical updates for two exon-skipping programs:

• ENTR-601-44 (exon 44): First patient clinical dataset expected in Q2 at a 6 mg/kg dose.
• ENTR-601-44: A second cohort with dose levels up to 12 mg/kg expected before year-end.
• ENTR-601-45 (exon 45): First cohort data expected in the middle of the year.

For the initial exon 44 readout at 6 mg/kg, Doshi said the key objectives are safety in patients and dystrophin production, building on what he described as a robust safety dataset from non-clinical work and a healthy volunteer study. He said the 6 mg/kg regimen consists of 5 mg/kg of the conjugate plus 1 mg/kg of the delivery vehicle.

On efficacy, Doshi said Entrada “readily expect[s]” to see double-digit dystrophin levels in the first cohort at 6 mg/kg. He added that dystrophin levels should be interpreted in the context of prior peer data, referencing Avidity’s del-zota program and stating it showed roughly 25% dystrophin above background. Doshi said Entrada expects to beat those levels in its second exon 44 cohort.

Safety and differentiation versus other approaches

During the discussion, Doshi contrasted Entrada’s cyclic cell-penetrating peptide chemistry with what he described as “linear peptide” approaches used by others. He said Entrada’s chemical structure has “very, very unique” characteristics and pointed to safety established in mice, non-human primates, and healthy volunteers.

Asked about PepGen’s DM1 data, Doshi said PepGen’s splicing results in DM1 “look pretty good,” while also raising concerns about potential safety liabilities tied to delivery vehicles. He emphasized Entrada’s ability to dose escalate, noting regulators have allowed dosing up to 12 mg/kg and 18 mg/kg in its programs, which he framed as an important part of therapeutic flexibility in pediatric and young adult populations.

Endpoints and functional measures

Doshi said that while dystrophin is a central biomarker, functional benefit is ultimately what matters. For the first cohorts in exon 44 and exon 45, he said the priority is safety and dystrophin production, and that functional benefit is being measured but is not expected to be seen in the initial cohort due to the short follow-up.

He noted that exon 44 patients have background dystrophin levels of roughly 6%–10%, which he suggested could make it take longer to demonstrate functional change. He contrasted that with exon 45, where he said lower background dystrophin could allow functional signals to emerge sooner.

Doshi described a study structure that includes a 19-week period with three doses, followed by an open-label period of roughly 39 weeks, suggesting that about one year of dosing and follow-up may be a more appropriate timeframe to assess functional benefit.

He also said Entrada plans to evaluate multiple functional endpoints and referenced broader field discussions about measures such as time to rise and other functional assessments, alongside regulatory and patient advocacy input.

U.S. enrollment plans and FDA dose limits

Doshi said Entrada has FDA approval to enroll an adult U.S. study, with current guidance to begin enrollment in the second half of the year. However, he said the company intends to review the upcoming 6 mg/kg exon 44 data and then discuss with the FDA whether it can increase U.S. dosing, noting the current U.S. cap is about 1.28 mg/kg.

He attributed the dose limitation to FDA conservatism in the absence of the later-generated 6 mg/kg healthy volunteer data, and said Entrada has had active discussions with FDA, including sharing and incorporating feedback on the ex-U.S. protocol. He said the company is weighing whether to proceed with the U.S. adult study as currently designed or pause and seek updated FDA feedback after reviewing the Q2 dataset.

Doshi added that because Entrada uses the same EEV across its exon 44, 45, 50, and 51 DMD programs—as well as in its DM1 collaboration with Vertex—he views a positive Q2 exon 44 dataset as a potential de-risking event for the broader portfolio.

About Entrada Therapeutics NASDAQ: TRDA

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.